Living organ donors take time off work and endure surgery to save the life of someone they may never meet. And we ask them to ...

Novartis has agreed to buy Regulus Therapeutics for up to $1.7 billion, giving the Swiss drugmaker access to an experimental ...

But maybe Edgar to start with you and with your expertise in the condition of autosomal dominant polycystic kidney disease, ...

Swiss pharmaceutical giant Novartis is poised to expand its profile in the San Diego area, announcing plans to acquire ...

Farabursen is being developed as a treatment for autosomal dominant polycystic kidney disease (ADPKD). This rare disease leads to the development of cysts in organs, mainly the kidneys.

Novartis will acquire Regulus Therapeutics for up to $1.7B, boosting its kidney drug pipeline with lead candidate farabursen.

Novartis has reached an agreement to buy Regulus Therapeutics and its experimental therapy for autosomal dominant polycystic ...

Pharma major Lupin Ltd on Thursday said it has received approval from the US health regulator for its generic version of ...

Announced Wednesday, the acquisition will hand the Swiss pharmaceutical firm a drug prospect called farabursen, which ...

Transaction includes USD 0.8 billion upfront with a potential additional USD 0.9 billion payment upon the achievement of a ...